Premium
Individualized toxicity‐titrated 6‐mercaptopurine increments during high‐dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study
Author(s) -
Frandsen Thomas L.,
Abrahamsson Jonas,
Lausen Birgitte,
Vettenranta Kim,
Heyman Mats,
Behrentz Michael,
Castor Anders,
Wehner Peder S.,
Frost Brittmarie,
Andersen Elisabeth W.,
Schmiegelow Kjeld
Publication year - 2011
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2011.08835.x
Subject(s) - toxicity , medicine , mercaptopurine , dosing , methotrexate , hematology , acute lymphocytic leukemia , chemotherapy , lymphoblastic leukemia , leukemia
Summary This study explored the feasibility and toxicity of individualized toxicity‐titrated 6‐mercaptopurine (6MP) dose increments during post‐remission treatment with High‐dose methotrexate (HDM) (5000 mg/m 2 , ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m 2 per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m 2 per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients ( P = 0·03). This study shows individualized toxicity‐titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.